Latest articles about Measles       Routine vaccines: Measles       Routine vaccines: Rubella

Gavi’s impact

The global number of reported cases more than doubled from 2017

Over 118 million children reached with measles or measles-rubella vaccine through routine immunisation

More than 524 million children immunised through measles and measles-rubella vaccination campaigns


GLOBAL NUMBER OF REPORTED CASES DOUBLES FROM 2017

While 2018 saw some progress in efforts to protect more children against measles, including successful immunisation campaigns in some of the largest Gavi-supported countries, the overall picture was not positive. The global number of reported cases more than doubled from 2017. Stagnating coverage rates led to multiple measles outbreaks worldwide, including in Gavi-supported countries such as India and Madagascar. Just 14 of the initial 73 Gavi-supported countries have been certified as having eliminated measles as a public health problem.

OVER 118 MILLION CHILDREN REACHED WITH MEASLES OR MEASLES-RUBELLA VACCINE THROUGH ROUTINE IMMUNISATION

By the end of 2018, our support for a second dose of measles vaccine through the routine immunisation system had helped immunise more than 76 million children. This support provides a second opportunity to reach children who missed the first dose. It also produces immunity in the small number of people who failed to develop it after the first dose. Since the programme start, Gavi has also reached over 42 million children with a first and/or second dose of measles-rubella vaccine.

OVER 524 MILLION CHILDREN IMMUNISED THROUGH MEASLES AND MR CAMPAIGNS

In order to have a long-term impact on both measles and rubella control, we have invested more than US$ 600 million in large-scale measles-rubella catch-up campaigns since 2012. This catalytic support requires countries to introduce MR vaccines into their routine system after a campaign. Gavi also supports measles and measles-rubella follow-up campaigns to address immunity gaps in the population and help build population immunity.

So far, over 275 million children have been immunised through Gavi-supported measles-rubella catch-up and follow-up campaigns, and over 249 through Gavi-supposed measles follow-up campaigns. Nationwide measles-rubella catch-up campaigns target all children aged 9 months to 14 years, while follow-up campaigns target children aged 9–59 months every 2–5 years.

The issue 

Measles remains one of the top vaccine-preventable killers of children.

Rubella infection in early pregnancy can result in foetal death or birth defects.

Measles remains one of the top vaccine-preventable killers of children.

Rubella infection in early pregnancy can result in foetal death or birth defects.

DISEASE BURDEN

Measles is a highly contagious virus and remains one of the top vaccine-preventable killers of children. Symptoms include high fever and a severe skin rash.  

Thanks to the widespread introduction of measles vaccine, global measles deaths have fallen dramatically. Before 2001, more than 750,000 children died every year from measles.  

But even with this impressive decline, progress has stalled, and the number of cases even increased in several countries. Outbreaks continue across Africa and Europe, with children under the age of five most affected. More than 95% of measles deaths occur in low-income countries with weak health systems.  

Rubella is no longer the threat it once was in many countries, thanks to widespread vaccination. But for millions of mothers and their children in low-income countries, it poses an ongoing danger. When a woman is infected with the rubella virus early in pregnancy, she has a 90% risk of passing the virus on to her foetus. This can cause miscarriage, stillbirth or severe birth defects known as congenital rubella syndrome (CRS).  

Every year, more than 100,000 babies are born with CRS - the majority in Africa and South-East Asia. Although the rubella vaccine has been available since the 1970s, it is still underused in these regions. 

Gavi’s response

Gavi’s support for measles and rubella vaccines is a game-changer in the control of two deadly and debilitating diseases.

Gavi’s support for measles and rubella vaccines is a game-changer in the control of two deadly and debilitating diseases.

NEW MEASLES AND RUBELLA STRATEGY  

2017 marked the first year of Gavi-supported measles vaccine introductions and campaigns under our new measles and rubella strategy. The bulk of our support for measles vaccine is allocated towards the combined measles-rubella (MR) vaccine, which also provides protection against congenital rubella syndrome.  

The revised approach involves increases in both vaccine support and introduction grants, as well as enhanced technical assistance from Alliance partners. It aims to help countries deliver high-quality plans, implementation and evaluation of routine programmes and campaigns. For instance, countries are required to conduct independent surveys to track campaign coverage.

During 2017, we increased our collaboration with the Measles & Rubella Initiative, which led to clear results in 2018. Focusing on the six countries with the highest number of underimmunised children led to successful immunisation campaigns in Nigeria and Pakistan – using polio eradication workers and systems, and enhanced collaboration between Alliance partners. This resulted in unprecedented levels of coverage: 89% in Nigeria and 93% in Pakistan, close to the 95% level required to confer herd immunity and with large numbers of previously unimmunised children reached.

Given the importance of increasing the number of people protected from measles, the Board also agreed to allow greater flexibility in the use of operational cost support funds to conduct more targeted activities. Burundi, Lesotho, Senegal and Zambia are among the countries expected to make use of this new flexibility.

The results from these campaigns and the options surrounding these flexibilities are good news, but they are no substitute for sustainable routine immunisation.

FOUR TYPES OF SUPPORT 

  • Measles and measles-rubella routine immunisation

Gavi supports a first and second dose of the MR vaccine, as well as second dose measles vaccines. Countries contribute to the cost of these Gavi-supported vaccines by co-financing some of the required doses.

Supporting a second dose of the vaccine provides a second opportunity to reach children who missed the first dose. It also produces immunity in the small number of persons who failed to develop it after the first dose

  • Measles follow-up campaigns  

Nationwide follow-up campaigns immunise children aged 9–59 months every 2–5 years with measles vaccine. These campaigns are aimed at addressing gaps in measles immunity in the population that is not reached through routine immunisation.

  • Measles-rubella catch-up and follow-up campaigns

Gavi provides support for measles-rubella vaccine catch-up campaigns before the MR vaccine is introduced into the routine system. The campaigns target children aged 9 months to 14 years. By catalysing the vaccine’s introduction into the routine immunisation system, they help to ensure long-term impact on both measles and rubella control efforts.

Measles-rubella follow-up campaigns are also supported by Gavi once the vaccine has been introduced into routine immunisation. Similar to measles follow-up campaigns, these campaigns are aimed at addressing gaps in measles immunity in the population.

  • Measles outbreak response (through the Measles & Rubella Initiative)

Gavi provided US$ 55 million to the Measles & Rubella Initiative (M&RI, formerly the Measles Initiative) for the 2013–2017 period. The funding is used for outbreak response in Gavi-supported countries.

M&RI is a global partnership committed to ensuring no child dies from measles or is born with congenital rubella syndrome. It is led by the American Red Cross, the United Nations Foundation, the U.S. Centers for Disease Control and Prevention, UNICEF and WHO. The M&RI aims to achieve the measles and rubella elimination goals outlined in the Global Vaccine Action Plan.

From other sites

Latest articles about Measles and measles-rubella

24 May 2023

Measles is surging, and Uzbekistan is bolstering its defences

It’s the most contagious human virus we have, expert at exploiting even slender gaps in a population’s collective immunity. Uzbekistan is vaccinating to stay a step ahead.

10 May 2023

Faith leaders join hands with health department to outflank measles in India’s Madhya Pradesh

State health officers think they’ve found the right people to preach the benefits of vaccination.

9 May 2023

Lesotho measles outbreak prompts mass vaccine campaign and awareness drive

Memories of a bad 2010 epidemic are spurring on the country’s health workers, as leaders say the campaign will run until every child is reached.

28 April 2023

An anatomy of an outbreak: Measles hits urban India

Measles ripped through Thane, near Mumbai, after immunisation coverage dipped during the pandemic. VaccinesWork visited the city to hear about its devastating impact, as well as how social factors may have helped its spread.

25 April 2023

Routine immunisation, extraordinary impact: Rubella

Rubella can severely affect babies in the womb, leading to birth defects including  heart problems and loss of hearing and eyesight. Yet even though it can be prevented by immunisation, many low-income countries don’t have enough vaccine coverage…

31 January 2023

Curbing measles in Kenya’s conflict-troubled Mandera County

Vaccine vials, clued-in parents, dedicated health workers... and armed police: VaccinesWork finds out what it takes to rein in a measles outbreak in Kenya’s north.

9 January 2023

Ukraine’s measles vaccine backlash illustrates the value of vaccine safety

A false attribution of bacterial meningitis to the measles vaccine in Ukraine in 2008 led to more than 130,000 cases of measles, 40 deaths and nearly US$ 140 million in economic damage worldwide. Gavi’s Dr Lee Hampton sets out the lessons we can…

22 December 2022

What happens when you don’t recover from the measles

In public health, we talk a lot about mortality and survival rates. But tallying who dies and who lives is a far-too-simple binary. The consequences of a disease often outlast the infection. This is the first instalment in a new series we’re…

22 December 2022

Measles blindness: Habeeb’s story

Measles is not just deadly. Some of those who survive suffer severe, sometimes total, eye damage. VaccinesWork met one mother in Nigeria desperately trying to save her son’s sight.

7 December 2022

Measles: why the World Health Organization has declared it an ‘imminent global threat’

Many children have missed a measles vaccine dose since the start of the COVID pandemic.

22 November 2022

“I will not wait for more to perish”: how two nurses in Lao PDR set out to immunise their province’s zero-dose kids

When a measles outbreak exposed just how frayed Savannakhet province’s immunisation safety net had grown during the COVID-19 pandemic, Nurses Manokra Khamsai and Kaysone Oum got to work mending it.

25 October 2022

Drama helps keep measles-rubella at bay in Papua New Guinea

A senior health worker and her team do everything in their power to get children vaccinated, including vaccination theatre.

20 October 2022

Zimbabwe conducts emergency measles campaign

The country embarked on emergency measles vaccination and re-vaccination for more than two million children under five years.

6 October 2022

Children in rich countries increasingly miss out on lifesaving vaccines

Fewer vaccines against diseases like measles, rubella and polio are being given to children in the UK, as numbers continue to fall year on year.

27 June 2022

What is a puskesmas and how are they spearheading Indonesia’s measles vaccinations?

The puskesmas is at the heart of health care for the poor and those in remote areas in Indonesia.

15 June 2022

How women in Ibasa, Nigeria, defy the odds to have their children immunised

Faced with multiple challenges, the women of Ibasa Community aren’t letting these get in the way of their children’s health.

8 June 2022

Measles vaccines offer hope in conflict-affected parts of Ethiopia

Recent vaccination campaigns in Afar and other regions are filling some of the gaps in routine immunisation brought about by recent conflict.

28 April 2022

Beyond the launch: three key lessons from Ethiopia on monitoring a new vaccine post-introduction

Vaccination of a second dose of measles vaccine (MCV2) has been introduced in many countries as a critical means to boost immunity and prevent disease from this highly contagious disease, yet coverage is lagging. We take a look at Ethiopia’s…

14 April 2022

Wanted: A vaccine against the measles

How the measles virus was trapped and tamed in vaccinology’s wild West.

11 April 2022

Europe at risk of measles resurgence as COVID-19 restrictions are eased

With many countries failing to hit measles vaccine coverage targets, and COVID-19 control measures being lifted, the goal of measles elimination hangs in the balance.

19 January 2022

Kisumu County’s 100-day immunisation campaign

In November 2021 Kenya’s Kisumu County launched a large scale measles-rubella vaccine campaign to reach 100% of unvaccinated children.

15 December 2021

Camel-borne vaccines and high-tech data systems: Inside Pakistan’s massive, historic measles-rubella vaccination campaign

Last month, Pakistan undertook one of its biggest-ever vaccination campaigns: 90 million doses of measles and rubella vaccine administered to 90 million children in just two weeks. #VaccinesWork was there.

29 November 2021

Routine vaccines, extraordinary impact: Measles

Measles is one of the world’s most contagious viruses. It can impair sight, hearing and cause brain inflammation and pneumonia. But even though it can be prevented by a vaccine, outbreaks in unvaccinated children continue to erupt even in the…

25 June 2021

Despite the pandemic, Kenya rolls out measles-rubella vaccinations

Beginning today, Kenya’s Ministry of Health is beginning a major new measles-rubella vaccination campaign to defend against outbreaks.

5 February 2021

Why do measles survivors get sicker?

Scientists wanted to find out about the long-term effect of measles on the immune system. Scientific article for students.

28 August 2020

How the Democratic Republic of the Congo overcame the world’s worst measles outbreak amid the COVID-19 pandemic

Before the pandemic began, the Democratic Republic of the Congo (DRC) was already facing a severe measles outbreak which started at the end of 2018. Despite huge challenges caused by COVID-19 and other diseases, the largest measles outbreak in…

13 August 2020

Somalia responds swiftly to measles outbreak in Jubaland State

A surveillance system in Somalia is providing real-time early warning disease alerts to help tackle health threats such as measles outbreaks and COVID-19 cases.

How to apply for vaccine support

May 6, 2021

Gavi Support Guidelines

Eligible countries can access detailed guidelines to manage the support they receive from Gavi.

Last updated: 1 May 2023

Subscribe to our newsletter